Search
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalActivation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the prob...
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]
Modified vaccinia ankara
go.drugbank.com/drugs/DB15483ApprovedInvestigationalModified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).
Amylocaine
go.drugbank.com/drugs/DB09088ApprovedWithdrawnEven though it certainly possessed less severe side effects than cocaine [L1882], the eventual development and clinical use of newer, more effective, and even safer local anesthetics like lidocaine, bupivicaine … Finally, in 1903 the world's first synthetic and non-addictive local anesthetic, amylocaine, was synthesized and patented under the name Forneaucaine by Ernest Fourneau at the Pasteur Institute [L1882]
Benzoctamine
go.drugbank.com/drugs/DB09021ExperimentalIt can be used as a sedative which does not depress the respiratory system, but rather stimulates it. … It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis.
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label].
Voclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigational[L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials. … Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared to older
Nitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedof illnesses caused by other protozoa or helminths [A31976]. … Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment
Leridistim
go.drugbank.com/drugs/DB15095InvestigationalLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).